WO2003004612A3 - Inhibitor of t cell activation - Google Patents

Inhibitor of t cell activation Download PDF

Info

Publication number
WO2003004612A3
WO2003004612A3 PCT/US2002/021215 US0221215W WO03004612A3 WO 2003004612 A3 WO2003004612 A3 WO 2003004612A3 US 0221215 W US0221215 W US 0221215W WO 03004612 A3 WO03004612 A3 WO 03004612A3
Authority
WO
WIPO (PCT)
Prior art keywords
activation
cell activation
inhibitor
localization
polypeptides
Prior art date
Application number
PCT/US2002/021215
Other languages
French (fr)
Other versions
WO2003004612A2 (en
Inventor
Sankar Ghosh
Acquisto Fulvio D
Original Assignee
Univ Yale
Sankar Ghosh
Acquisto Fulvio D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Sankar Ghosh, Acquisto Fulvio D filed Critical Univ Yale
Priority to AU2002316552A priority Critical patent/AU2002316552A1/en
Publication of WO2003004612A2 publication Critical patent/WO2003004612A2/en
Publication of WO2003004612A3 publication Critical patent/WO2003004612A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides polynucleotides, polypeptides, pharmaceutical compositions, and methods for modulation of PKCθ activation, T-cell activation, NF-λB activation, and supramolecular activation cluster assembly and localization.
PCT/US2002/021215 2001-07-02 2002-07-02 Inhibitor of t cell activation WO2003004612A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002316552A AU2002316552A1 (en) 2001-07-02 2002-07-02 Inhibitor of t cell activation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30247401P 2001-07-02 2001-07-02
US60/302,474 2001-07-02

Publications (2)

Publication Number Publication Date
WO2003004612A2 WO2003004612A2 (en) 2003-01-16
WO2003004612A3 true WO2003004612A3 (en) 2003-04-24

Family

ID=23167861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/021215 WO2003004612A2 (en) 2001-07-02 2002-07-02 Inhibitor of t cell activation

Country Status (2)

Country Link
AU (1) AU2002316552A1 (en)
WO (1) WO2003004612A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
EP1657305A4 (en) * 2003-08-19 2007-03-28 Celestar Lexico Sciences Inc Interaction inhibitors, method of detecting interaction inhibitor and kit for detecting interaction inhibitor
DE102005020754B3 (en) * 2005-05-02 2007-01-11 Altana Pharma Ag Cellular assay method for the identification of PKCtheta inhibitors
WO2008140484A2 (en) 2006-11-09 2008-11-20 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
US20150099645A1 (en) * 2012-03-14 2015-04-09 Stephen Marx Means and methods for diagnostics and therapeutics of diseases
EP3180003B1 (en) 2014-07-01 2022-01-12 The Regents of the University of California Pkc-epsilon inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190869B1 (en) * 1999-10-26 2001-02-20 Isis Pharmaceuticals, Inc. Antisense inhibition of protein kinase C-theta expression
WO2001048236A1 (en) * 1999-12-27 2001-07-05 La Jolla Institute For Allergy METHODS FOR IDENTIFYING AGENTS CAPABLE OF MODULATING PROTEIN KINASE C THETA (PKCυ) ACTIVITY

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190869B1 (en) * 1999-10-26 2001-02-20 Isis Pharmaceuticals, Inc. Antisense inhibition of protein kinase C-theta expression
WO2001048236A1 (en) * 1999-12-27 2001-07-05 La Jolla Institute For Allergy METHODS FOR IDENTIFYING AGENTS CAPABLE OF MODULATING PROTEIN KINASE C THETA (PKCυ) ACTIVITY

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAIER G. ET AL.: "Molecular cloning and characterization of PKC-zeta, a novel member of the protein kinase C (PKC) gene family expressed predominantly in hematopoietic cells", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 7, 5 March 1993 (1993-03-05), pages 4997 - 5004, XP002958565 *
CHOU M. ET AL.: "Regulation of protein kinase C zeta by PI 3-kinase and PDK-1", CURRENT BIOLOGY, vol. 8, no. 19, 1998, pages 1069 - 1077, XP002958564 *
SOUMITRO P. ET AL.: "Role of protein kinase zeta in ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression", J. OF BIOLOGICAL CHEMISTRY, vol. 276, no. 4, 26 January 2001 (2001-01-26), pages 2395 - 2403, XP002958566 *

Also Published As

Publication number Publication date
AU2002316552A1 (en) 2003-01-21
WO2003004612A2 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
AU2001287870A1 (en) Microfabricated reaction chamber system
EP1293503A4 (en) Triazole derivatives
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
WO2000025723A3 (en) Methods and compositions for the prevention of tolerance to medications
WO2001091699A3 (en) Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways
WO2001083554A3 (en) Anti-inflammatory compounds and uses thereof
WO1999003822A8 (en) Bicyclic metabotropic glutamate receptor ligands
WO2005045689A3 (en) Methods and systems for network coordination
WO2001098236A3 (en) 7-phenyl-substituted tetracycline compounds
WO2002100244A3 (en) Microfabricated surgical device
AU2002344842A1 (en) Highly impact-resistant granules
EP1535907A4 (en) Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
WO1999020747A3 (en) HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS
WO2003004612A3 (en) Inhibitor of t cell activation
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
AU2002355938A1 (en) Footwear system
CA2284142A1 (en) Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
WO2003007912A3 (en) Lyophilized formulation comprising olanzapine
CA2251241A1 (en) Apoptosis inhibitor
AU2002325591A1 (en) Toggle retainer for toggle connections
WO2000073345A3 (en) Antibodies specific for mycobacterial polypeptides and uses thereof
WO2004006866A3 (en) Antifungal therapeutic targets
WO2001060857A3 (en) Compositions useful for regulating parkin gene activity
WO2003048106A3 (en) 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP